ELVN vs KYMR vs RVMD vs IMVT vs AUPH

For growth investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger pick with 20. 4% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 7. 3x trailing P/E (18. 6x forward), making it the more compelling value choice. Analysts rate Enliven Therapeutics, Inc. (ELVN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Revolution Medicines, Inc.

(RVMD) delivered a total return of +382. 1%, compared to +38. 9% for Enliven Therapeutics, Inc. (ELVN). Over 10 years, the gap is even starker: AUPH returned +508. 0% versus ELVN's -32. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aurinia Pharmaceuticals Inc.

(AUPH) is the lower-risk stock at 0. 86β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 59% more volatile than AUPH relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 13% for Aurinia Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aurinia Pharmaceuticals Inc.

(AUPH) is pulling ahead at 20. 4% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to -66. 2% for Revolution Medicines, Inc.. Over a 3-year CAGR, AUPH leads at 28. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurinia Pharmaceuticals Inc.

(AUPH) is the more profitable company, earning 101. 5% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 67.

2% to $45. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +508. 0% 10Y return). Both have compounded well over 10 years (AUPH: +508. 0%, ELVN: -32. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELVN is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; RVMD is a mid-cap quality compounder stock; IMVT is a small-cap quality compounder stock; AUPH is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.